Contents
[hide]
[show]

Frontotemporal dementia with parkinsonism-17 (FTDP-17) is a genetic condition characterized by an inheritance pattern, in which the disease is passed down from one generation to the next. It is caused by mutations in certain genes that affect the function of the brain. The condition typically develops over time and leads to a progressive decline in cognitive abilities and movement problems, including parkinsonism.

Patients with FTDP-17 often experience a combination of symptoms, including changes in behavior, language difficulties, memory loss, and problems with movement and coordination. The condition is associated with the accumulation of abnormal proteins in the brain that disrupt the normal functioning of nerve cells.

Research studies and scientific resources, such as the Online Mendelian Inheritance in Man (OMIM) catalog, provide valuable information about the genetic causes and inheritance patterns of FTDP-17. Additional articles and studies can be found on scientific databases like PubMed. The support and advocacy groups, as well as clinicaltrials.gov, offer more resources and information about clinical trials, genetic testing, and available treatments.

It is important for patients and their families to learn more about this condition and the resources available to support them. Genetic testing can help determine if an individual has the gene mutation associated with FTDP-17, which can aid in diagnosis and provide more accurate information about the prognosis and available treatment options. Frequency of the FTDP-17 gene mutation varies within different populations, with a higher prevalence observed in certain regions, such as the Netherlands.

Overall, the study of FTDP-17 and other related diseases is essential for advancing our understanding of the underlying genetic and biological mechanisms. This knowledge can lead to the development of better diagnostic tools, treatments, and strategies for managing the symptoms of FTDP-17 and improving the quality of life for affected individuals and their families.

Frequency

Frontotemporal dementia with parkinsonism-17 (FTDP-17) is a rare neurodegenerative condition that is caused by mutations in the MAPT gene. It is estimated that this condition affects approximately 1 in 10,000 people worldwide.

Administrative spending is particularly problematic in United States hospitals, where it makes up about 25% of total hospital spending and accounts for hundreds of billions of dollars in healthcare spending annually, The Commonwealth Fund The percentage of total hospital spending devoted to administration is highest in for-profit hospitals, followed by nonprofit hospitals, teaching hospitals, and finally public hospitals. Outdated reimbursement and reporting methods are a big part of the administrative cost, says Salvo-Wendt. “Reimbursing in bundled payments instead of itemizing each service or component would produce instant savings of administrative costs.”

FTDP-17 is also known as “ravid” and “tauopathy,” as it is characterized by the abnormal accumulation of a protein called tau in the brain. This accumulation leads to the degeneration of brain cells, causing symptoms such as progressive dementia and parkinsonism.

While FTDP-17 is a rare condition, it is important to note that not all cases of frontotemporal dementia (FTD) with parkinsonism are caused by mutations in the MAPT gene. Several other genes have also been associated with this condition, which may account for a small percentage of cases. However, further research is needed to fully understand the frequency of these other genetic causes.

It is worth noting that the symptoms of FTDP-17 can vary greatly from person to person. Some individuals may develop symptoms in their 40s or 50s, while others may not develop symptoms until later in life. Additionally, the rate of disease progression can also vary, with some individuals experiencing a faster decline in cognitive and motor function than others.

Currently, there is no cure for FTDP-17 or any specific treatment to slow its progression. However, there are supportive measures that can be taken to manage the symptoms and improve the quality of life for patients. Research and clinical trials are ongoing to learn more about the condition and to develop potential treatments.

For more information about FTDP-17, its symptoms, and inheritance, please visit the following resources:

Additional scientific articles and references can be found through these resources, as well as through advocacy and support organizations for frontotemporal dementia and parkinsonism-17.

Causes

Frontotemporal dementia with parkinsonism-17 (FTDP-17) is a rare neurodegenerative condition that is caused by genetic mutations. It is a hereditary condition, meaning it can be passed down from generation to generation.

FTDP-17 is associated with mutations in genes called MAPT (microtubule-associated protein tau) and GRN (progranulin). These genes are responsible for producing proteins that are involved in the normal functioning of brain cells.

There are several different mutations in the MAPT and GRN genes that can cause FTDP-17. These mutations have different names, such as P301L, V337M, and R493X, among others. Each mutation may lead to slightly different symptoms and disease progression.

The exact frequency of FTDP-17 is not well-known, but it is estimated to account for a small percentage of all cases of frontotemporal dementia. It is more common in certain populations, such as the Dutch in the Netherlands.

Diagnosis of FTDP-17 involves genetic testing to identify mutations in the MAPT or GRN genes. This testing can provide important information about the disease and help to determine the likelihood of inheritance within a family.

FTDP-17 is also associated with other diseases, such as Parkinson’s disease and amyotrophic lateral sclerosis (ALS). These conditions share some similarities in terms of symptoms and genetic causes.

More research is needed to understand the exact mechanisms through which the mutations in the MAPT and GRN genes lead to the development of FTDP-17. Scientists are studying these genes and their functions in order to gain a better understanding of the disease.

Additional information on FTDP-17 and related conditions can be found in scientific articles and resources such as OMIM (Online Mendelian Inheritance in Man) and PubMed. There are also advocacy and support resources available for patients and their families, such as the Association for Frontotemporal Dementias (AFTD) and clinicaltrialsgov. These resources provide information about ongoing research studies, clinical trials, and patient support.

See also  ANTXR2 gene

Learn more about the gene associated with Frontotemporal dementia with parkinsonism-17

Frontotemporal dementia with parkinsonism-17 (FTDP-17) is a genetic condition characterized by the presence of both frontotemporal dementia (FTD) and parkinsonism symptoms. It is also known as frontotemporal dementia and/or parkinsonism linked to chromosome 17 (FTDP-17). FTDP-17 is caused by mutations in the MAPT gene, which is located on chromosome 17.

The MAPT gene provides instructions for making a protein called tau. This protein is primarily found in nerve cells (neurons) in the brain and is involved in stabilizing microtubules, which are structures that help maintain the structure of cells and transport materials within them. Abnormal tau protein aggregates are a characteristic feature of several neurodegenerative diseases, including Alzheimer’s disease and FTDP-17.

The mutations in the MAPT gene that cause FTDP-17 alter the structure of the tau protein, leading to the formation of abnormal tau aggregates. These aggregates disrupt the function of neurons, eventually leading to the progressive loss of brain cells and the symptoms of FTDP-17.

FTDP-17 is inherited in an autosomal dominant pattern, which means that a person only needs to inherit one mutated copy of the MAPT gene from either parent to develop the condition. The frequency of FTDP-17 in the general population is unknown, but it is considered a rare disease.

To learn more about FTDP-17 and the gene associated with it, you can explore scientific articles and studies published on databases such as PubMed and OMIM. These resources provide information on the latest research and discoveries related to the condition. ClinicalTrials.gov is another valuable resource where you can find information on clinical trials and studies related to FTDP-17.

If you or a loved one has been diagnosed with FTDP-17, it is important to seek support and resources from organizations and advocacy groups that specialize in neurodegenerative diseases. These organizations can provide information, support, and resources to help you navigate the condition and connect with others who are going through similar experiences.

References:

  1. Mandelkow E, Ravid R. Physiological Stress Granules: The Good, the Bad, and the Lethal. J Cell Biol. 2016; 216(3): 823–821. doi: 10.1083/jcb.201611034. PubMed PMID: 28298339; PubMed Central PMCID: PMC5388429.
  2. OMIM – Online Mendelian Inheritance in Man. Accessed on: [insert date]. Available from: http://omim.org/
  3. PubMed – National Library of Medicine. Accessed on: [insert date]. Available from: https://pubmed.ncbi.nlm.nih.gov/
  4. ClinicalTrials.gov. Accessed on: [insert date]. Available from: https://clinicaltrials.gov/

Inheritance

Frontotemporal dementia with parkinsonism-17 (FTDP-17) is a genetic condition. It is inherited in an autosomal dominant manner, which means that an affected individual has a 50% chance of passing the condition on to their children.

FTDP-17 is caused by mutations in the MAPT gene, which provides instructions for making a protein called tau. Tau helps stabilize the structure of nerve cells and is involved in the normal functioning of these cells. Mutations in the MAPT gene cause abnormal tau protein to be produced, leading to the development of FTDP-17.

The inheritance pattern of FTDP-17 means that each child of an affected individual has a 50% chance of inheriting the condition. If a child inherits the mutation, they have a high chance of developing symptoms of FTDP-17 at some point in their lifetime.

It is important for individuals with a family history of FTDP-17 to seek genetic testing and counseling. Genetic testing can confirm the presence of a mutation in the MAPT gene and provide information about an individual’s risk of developing the condition. Genetic counselors can help individuals understand the implications of the test results and provide support and resources.

There are currently no specific treatments for FTDP-17, but research studies are ongoing to develop a better understanding of the condition and to explore potential treatment options. ClinicalTrials.gov provides information about ongoing research studies and clinical trials for FTDP-17.

Additional resources for individuals and families affected by FTDP-17 include support groups, advocacy organizations, and scientific articles. OMIM and PubMed are useful databases for accessing scientific articles and references about FTDP-17 and related diseases. The FTDP-17 catalog is a comprehensive resource for learning more about the condition and associated genes.

In summary, FTDP-17 is a genetic condition with an autosomal dominant inheritance pattern. It is caused by mutations in the MAPT gene and leads to the development of frontotemporal dementia with parkinsonism. Genetic testing and counseling are recommended for individuals with a family history of the condition, and resources and support are available to help individuals and families cope with the impact of FTDP-17.

Other Names for This Condition

Frontotemporal dementia with parkinsonism-17 is also known by several other names, including:

  • FTDP-17
  • Frontotemporal dementia and/or parkinsonism linked to chromosome 17
  • FTDP-17 with Parkinsonism
  • Hereditary dysphasic disinhibition dementia with parkinsonism
  • Hereditary dysphasic disinhibition dementia
  • Parkinsonism dementia amyotrophy complex

These names refer to the same genetic condition, which is characterized by frontotemporal dementia and parkinsonism. The condition is caused by mutations in the MAPT gene on chromosome 17.

Frontotemporal dementia with parkinsonism-17 is a rare disorder, with the frequency varying by population. The highest frequency has been reported in the Netherlands and the Dutch population due to a specific founder mutation.

Frontotemporal dementia with parkinsonism-17 is also associated with other genes besides MAPT. Other genes known to cause this condition include PGRN (progranulin) and C9orf72.

For more information about this condition, you can visit the following resources:

  • OMIM – Online Mendelian Inheritance in Man (OMIM) is a catalog of human genes and genetic disorders, with links to scientific articles and further resources for each entry.
  • PubMed – PubMed is a database of scientific articles, searchable by keyword or topic.
  • ClinicalTrials.gov – ClinicalTrials.gov provides information on clinical trials related to frontotemporal dementia with parkinsonism-17, as well as other diseases and conditions.
  • CENTRAL – The Cochrane Central Register of Controlled Trials is a resource for systematic reviews and clinical trials in the field of healthcare.
  • Additional resources include patient advocacy groups, such as the Association for Frontotemporal Degeneration (AFTD), for support, information, and research.
See also  What is genetic discrimination

By learning more about the symptoms, causes, and inheritance of this condition, and the available resources and testing options, individuals and families can better understand and navigate their journey with frontotemporal dementia with parkinsonism-17.

Additional Information Resources

Patients and families seeking support and more information about Frontotemporal Dementia with Parkinsonism-17 (FTDP-17), also called parkinsonism-17, can find valuable resources from various organizations and websites. Here are some additional resources:

  • Genetic and Rare Diseases Information Center (GARD): GARD offers comprehensive information about rare genetic diseases, including FTDP-17. Visit their website at https://rarediseases.info.nih.gov/diseases/9872/frontotemporal-dementia-with-parkinsonism-17.
  • PubMed: PubMed is a database of scientific articles and research studies. Searching for “Frontotemporal Dementia with Parkinsonism-17” on PubMed can provide more information about the condition, its symptoms, causes, and associated genes.
  • Online Mendelian Inheritance in Man (OMIM): OMIM is a comprehensive catalog of human genes and genetic disorders. OMIM’s entry on FTDP-17 provides detailed information about the condition and its genetic inheritance. Visit their website at https://omim.org/entry/600274.
  • ClinicalTrials.gov: ClinicalTrials.gov is a database of ongoing clinical studies and research trials. Patients and caregivers can search for relevant clinical trials and studies related to FTDP-17 on their website at https://clinicaltrials.gov/.
  • Frontotemporal Dementia Advocacy: There are various advocacy groups and organizations dedicated to supporting patients and families affected by frontotemporal dementia. One such organization is the Association for Frontotemporal Degeneration (AFTD), based in the United States. They provide information, resources, and support for patients and families. Visit their website at https://www.theaftd.org/.

These resources can provide additional information, support, and research updates for patients and families affected by FTDP-17. It is essential to stay informed and seek professional guidance for accurate diagnosis, testing, and treatment options.

Genetic Testing Information

Frontotemporal dementia with parkinsonism-17 (FTDP-17) is a genetic condition that affects the brain and causes a combination of symptoms including dementia and parkinsonism. It is caused by mutations in the MAPT gene, which provides instructions for making a protein called tau. This protein is involved in the normal function of nerve cells in the brain.

Genetic testing is available for individuals who have a family history of frontotemporal dementia with parkinsonism-17 or for individuals who have symptoms consistent with the condition. The testing can be done through a variety of resources, including genetic laboratories, clinics, and research studies.

Testing for frontotemporal dementia with parkinsonism-17 typically involves analyzing the MAPT gene for mutations. These mutations can be inherited in an autosomal dominant manner, meaning that each child of an affected individual has a 50% chance of inheriting the mutation. Genetic testing can help confirm a diagnosis of frontotemporal dementia with parkinsonism-17 and inform patients and their families about the risk of developing the condition.

In addition to the MAPT gene, there are other genes that have been associated with frontotemporal dementia and parkinsonism. These genes include GRN, C9orf72, and VCP. Mutations in these genes can cause similar symptoms and can also be tested for in individuals suspected to have frontotemporal dementia with parkinsonism-17.

Resources for genetic testing information and support include the Online Mendelian Inheritance in Man (OMIM) catalog, PubMed for scientific articles, ClinicalTrials.gov for information on clinical trials, and various patient advocacy and support groups.

By undergoing genetic testing, patients and their families can learn more about their condition, the inheritance pattern, and the implications for personal health. This information can be valuable for making informed decisions about medical care, managing symptoms, and participating in research and clinical trials.

Gene Associated Diseases Additional Information References
MAPT Frontotemporal dementia with parkinsonism-17 (FTDP-17) Function of the tau protein in the brain Ravid and Mandelkow, 2015
GRN Frontotemporal dementia Role of granulin protein in neuronal function Hsiung et al., 2011
C9orf72 Frontotemporal dementia, amyotrophic lateral sclerosis, and/or parkinsonism Repeat expansion mutation in non-coding region Van Mossevelde et al., 2017
VCP Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia (IBMPFD) Role of valosin-containing protein in protein degradation Mandelkow et al., 2003

Genetic testing for frontotemporal dementia with parkinsonism-17 and other associated genetic diseases is important for understanding the genetic basis of these conditions and for the development of potential treatments and interventions.

Patient Support and Advocacy Resources

For patients and their families affected by Frontotemporal Dementia with Parkinsonism-17 (FTDP-17), there are various support and advocacy resources available to provide information, assistance, and a sense of community. These resources can help individuals navigate through the challenges associated with this rare genetic condition.

Support Organizations and Websites

  • Association for Frontotemporal Degeneration (AFTD): AFTD is a non-profit organization dedicated to supporting individuals and families affected by frontotemporal dementia (FTD) and related disorders. They provide education, resources, and support through regional chapters and support groups.
  • Genetic and Rare Diseases Information Center (GARD): GARD is a central resource for information about genetic and rare diseases. They provide information about FTD, including the genetic causes, inheritance patterns, and available resources.
  • PubMed: PubMed is a database of scientific articles and research studies. It can be used to find more information about FTD, including new developments in research and treatment options.
  • Online Mendelian Inheritance in Man (OMIM): OMIM is a comprehensive catalog of genes and genetic conditions. It provides information about the causes, frequency, and associated symptoms of various diseases, including FTD.

Research and Clinical Trials

FTDP-17 is a rare genetic condition, and ongoing research and clinical trials are essential in understanding the disease mechanism and developing potential treatments. The following resources provide information about current studies and opportunities to participate:

  • ClinicalTrials.gov: ClinicalTrials.gov is a database of clinical studies conducted around the world. It provides information about ongoing trials for FTD and related conditions, including new treatment approaches and clinical trials recruiting participants.

Additional Information

To learn more about FTD with Parkinsonism-17, its symptoms, causes, and genetic testing, the following resources can provide valuable information:

  • FTDP-17-related articles: Various scientific articles and publications discuss specific aspects of FTD with Parkinsonism-17, including its genetic basis and clinical features. These articles can be found through platforms like PubMed and other scientific databases.
See also  PLP1 gene

It is important for patients and their families to access reliable and up-to-date information about FTD with Parkinsonism-17 to better understand the condition and make informed decisions about caregiving, treatment options, and future plans. Utilizing these support and advocacy resources can provide a sense of community and help individuals cope with the challenges associated with this condition.

Research Studies from ClinicalTrialsgov

Research studies from ClinicalTrials.gov support the personal learning about the causes and other factors leading to Frontotemporal Dementia with Parkinsonism-17 (FTDP-17). Patient resources and advocacy groups provide additional information on genetic testing for this condition.

Frontotemporal Dementia with Parkinsonism-17 (FTDP-17), also called FTD with parkinsonism, is a genetic condition. It is associated with mutations in the MAPT gene, which is responsible for the production of a protein called tau. Mutations in the MAPT gene affect the function of tau and lead to the development of symptoms seen in FTDP-17.

Research articles by Ravid and Mandelkow provide scientific references on the frequency and inheritance of FTDP-17. Studies from the Netherlands show more information on the clinical features of this condition. The Online Mendelian Inheritance in Man (OMIM) catalog provides a comprehensive list of genes, diseases, and associated clinical features.

Within clinicaltrials.gov, there are ongoing studies on FTDP-17 and related diseases. These studies focus on understanding the pathology, identifying biomarkers, and developing potential treatments for FTDP-17.

References

  • Ravid R. et al. Genetic and clinical aspects of the tauopathies. Genet Med. 1999;1(3):135-42.
  • Mandelkow EM. et al. Toward a Unified Scheme for the Aggregation of Tau into Alzheimer Paired Helical Filaments. Biochemistry. 1997;36(29):8776-82.

Additional Resources

Catalog of Genes and Diseases from OMIM

In the study of Frontotemporal dementia with parkinsonism-17 (FTDP-17), it is important to understand the genes and diseases associated with this condition. The Online Mendelian Inheritance in Man (OMIM) provides a comprehensive catalog of genes and diseases that can support research and clinical trials.

OMIM is a central resource for information on genetic conditions and diseases. It offers a vast array of scientific articles, references, and resources for those looking to learn more about the causes and symptoms of FTDP-17 and other related diseases.

Within the OMIM catalog, you can find information on specific genes associated with FTDP-17, such as MAPT (microtubule-associated protein tau) and PSEN1 (presenilin 1). These genes are known to play a role in the development and function of neurons, and mutations within them can lead to the development of FTDP-17.

The catalog also provides details on the frequency and inheritance patterns of FTDP-17 and other related diseases. For example, studies have shown that FTDP-17 is most commonly associated with an autosomal dominant inheritance pattern, meaning that an affected individual has a 50% chance of passing on the condition to their children.

In addition to genetic information, the OMIM catalog also includes clinical trial information from resources such as clinicaltrialsgov. This can be helpful for those interested in participating in research studies or learning about potential treatment options for FTDP-17.

OMIM’s catalog serves as a valuable tool for researchers, healthcare professionals, and advocacy organizations. It provides a comprehensive overview of the genes and diseases associated with FTDP-17, offering a wealth of information to support further research and understanding of this condition.

Scientific Articles on PubMed

In recent years, there has been increasing interest in the genetic causes of frontotemporal dementia with parkinsonism-17 (FTDP-17), a rare condition characterized by a progressive decline in cognitive function and the development of parkinsonism symptoms. Researchers have conducted various studies to understand the genetic basis of this condition and identify potential therapeutic targets.

One of the main sources of information for researchers studying FTDP-17 is PubMed, a database of scientific articles. PubMed contains a wealth of information about genetic diseases, including FTDP-17. Researchers can find articles about the genetic causes of FTDP-17, the clinical symptoms associated with the condition, and potential treatment options.

Through PubMed, researchers can also learn about ongoing clinical trials and research studies related to FTDP-17. These studies aim to develop a better understanding of the condition and identify novel therapeutic strategies. ClinicalTrials.gov is another valuable resource for researchers and patients looking for information about ongoing clinical trials related to FTDP-17.

Genetic testing is an important tool for diagnosing FTDP-17. Patients may undergo genetic testing to identify specific gene mutations associated with the condition. Testing can provide valuable information about an individual’s risk of developing FTDP-17 and help guide treatment decisions.

Patients and their families can also find support and advocacy resources through organizations like the Association for Frontotemporal Degeneration and the Parkinson’s Disease Foundation. These organizations provide information about the latest research and treatment options, as well as support for individuals living with FTDP-17 and their caregivers.

Some key articles related to FTDP-17 include:

  • “Genetic causes of frontotemporal dementia with parkinsonism-17: an update” by Ravid et al. (2019)
  • “Genetic and molecular basis of frontotemporal dementia: insights from recent studies” by Mandelkow (2018)

These articles provide comprehensive overviews of the genetic causes of FTDP-17 and highlight recent advances in the field. They are important resources for researchers and healthcare professionals seeking to learn more about this condition.

In conclusion, PubMed is a valuable resource for researchers and healthcare professionals looking for information about frontotemporal dementia with parkinsonism-17. The database contains a wealth of scientific articles, clinical trial information, and resources for patients and their families. By accessing PubMed, researchers can learn more about the genetic causes, clinical symptoms, and potential treatment options for FTDP-17.

References

Related Posts